<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04774939</url>
  </required_header>
  <id_info>
    <org_study_id>93 /1801/2020</org_study_id>
    <nct_id>NCT04774939</nct_id>
  </id_info>
  <brief_title>EVLA and Optimal Timing of Sclerotherapy</brief_title>
  <acronym>FinnTrunk</acronym>
  <official_title>FinnTrunk, EVLA and Optimal Timing of Sclerotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Päijänne Tavastia Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Satasairaala</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vaasa Central Hospital, Vaasa, Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the optimal timing of sclerotherapy for treatment of&#xD;
      varicose tributaries on EVLA (endogenous laser ablation) patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study inclusion criteria is patients with main trunk (VSM, SSV, AASV) reflux to be&#xD;
      treated with EVLA, suffering C2-C3 varicose disease, age 18-years and no severe&#xD;
      co-morbidities.&#xD;
&#xD;
      Patients with written consent will be randomized to two primary treatments groups; EVLA only&#xD;
      and EVLA combined with sclerotherapy of varicose tributaries. The primary outcome is the&#xD;
      requirement additional sclerotherapy on 3 month control visit. Other study outcomes are pain,&#xD;
      quality of life (veins questionnaire), severity score and also recurring of varicose disease&#xD;
      at 1, 3 and 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 15, 2021</start_date>
  <completion_date type="Anticipated">March 15, 2030</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>re-intervention</measure>
    <time_frame>3 months</time_frame>
    <description>Requirement of re-intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain after procedure</measure>
    <time_frame>up to 3 months after the treatment</time_frame>
    <description>Post procedural pain measured with VAS scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life before after procedure</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Quality of life will be measured with Veins questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recur</measure>
    <time_frame>up to 5 years</time_frame>
    <description>The recurring varicose veins</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical complications</measure>
    <time_frame>3 months</time_frame>
    <description>Infections, DVT, Pulmonary embolus will be reported</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Venous Reflux</condition>
  <arm_group>
    <arm_group_label>EVLA only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Only main trunk/trunks with venous reflux will be treated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EVLA and sclerotherapy of tributaries</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Main trunk/trunks with venous reflux will be treated combined with foam sclerotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endovenous laser ablation</intervention_name>
    <description>The aim is to combine the significance of for sclerotherapy at the primary EVLA treatment</description>
    <arm_group_label>EVLA and sclerotherapy of tributaries</arm_group_label>
    <arm_group_label>EVLA only</arm_group_label>
    <other_name>Endovenous laser ablation combined with foam sclerotherapy of varicose tributaries</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Varicose disease of lower extremity caused by reflux of VSM, SSV or AASV to be treated&#xD;
             with EVLA. Age over 18 years. Clinical symptoms C2-3.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No severe comorbidities. Previous DVT.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harri Hakovirta, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>University of Turku</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Harri Hakovirta, Professor</last_name>
    <phone>+358405918811</phone>
    <email>haheha@utu.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Khalil Firoozi, MD</last_name>
    <phone>+35823130000</phone>
    <email>khalil.firoozi@tyks.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Harri Hakovirta, Professor</last_name>
      <phone>+35823130000</phone>
      <email>harri.hakovirta@tyks.fi</email>
    </contact>
    <contact_backup>
      <last_name>Khalil Firoozi, MD</last_name>
      <phone>+35823130000</phone>
      <email>khalil.firoozi@tyks.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Jaakko Viljamaa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 24, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Turku University Hospital</investigator_affiliation>
    <investigator_full_name>Khalil Firoozi</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

